Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is a E-Mail i Just received from the DA office -
Dear *******
Thank you I will pass it on to the Chief, as well as the Commander of Investigations and our Evidence Technicians.
>>> "*** ******" <8888888888888888> 02/14/04 12:43PM >>>
Dear Mr. Gilloffo
Below is a comp. who is helping to fight Crime by way of Dna
testing. They are able to tell Your Race, and eye color from your DNA.And soon will be able to tell your HAIR color as well. Please forward to Chief of Police and other units. For your review -
DNAWitnessT Used to Guide the Investigation of the '97 rape and murder of Susannah Chase DNAPrint genomics (OTCBB: DNAP) of Sarasota, FL confirmed that its DNAWitnessT test was strategically employed in an investigation by the
Boulder, Colorado Police Department.
Susannah Chase, 23 was brutally beaten and raped in December of 1997.
Her body, as well as a DNA specimen, was found several days later.
A representative of the Boulder Police Department has stated, "DNAPrint
reported that the DNA investigators submitted is indicative of someone
exhibiting features that are common to Hispanics or Native Americans.
This information will assist detectives with prioritizing tips and
possibly generate more investigative leads."
DNA is commonly left at crime scenes, but until DNAPrintT developed
DNAWitnessT, no ancestral or physical information could be reliably read
from that DNA (other than gender). The genetic heritage of an
individual cannot be accurately inferred from standard DNA tests.
DNAWitnessT is powered by 175 of the human genome's best Ancestry
Informative Markers (AIMs) and measures an individual's ancestry
admixture from his or her DNA. From simulations and direct
observations, it is known that DNAWitness results are precise to within
a few percent, depending on the type of admixture present.
Standard DNA testing provides a unique identifier from the crime scene
DNA, but in this case, the crime scene DNA did not match any of the
profiles in the FBI's CODIS database, making the identification of the
suspect impossible at this time. Detectives continued their quest to
learn about the donor of the DNA at the crime scene and their search led
investigators to DNAPrint genomicsT, which is the first and so far only
company able to offer this new type of DNA analysis. The test was
applied by investigators to infer physical information about the suspect
from the crime scene DNA, allowing them to focus precious investigative
resources on high value leads related to the crime.
Forensic validation studies of DNAWitnessT have been performed by the
San Diego Police Department Crime Lab, the National Center for Forensic
Science and the Broward County Crime Lab. In July, 2003, a report in
the Journal of Forensic Science provided the scientific rationale and
results of studies related to DNAWitnessT, and the test has since been
covered by Popular Science, US News and World Report, the New York
Times, and national ABC and CBS news programs. DNAPrint genomics T has
successfully determined the ancestral background of over 5,000
individuals.
"We are working with detectives on cases that have gone cold or are at
a standstill," said Richard Gabriel, CEO and President of DNAPrint
genomics, Inc., "we encourage all law enforcement officers to contact
us. In this case, as in others, when DNA WitnessT has been used, the
scope of the investigation has been focused, and resources will be more
efficiently deployed. DNAWitnessT is proving to save time and resources
-- and possibly lives -- by contributing valuable information about a
suspect's ancestry. If there is a crime scene sample of DNA,
DNAWitnessT can help re-direct or focus the investigation. Prior to this
test, this case would remain unsolved until the murderer is caught
committing another crime and that convicted felon's DNA is loaded into
the CODIS system."
"The test costs $1,000, but given the man hours this test can save and
direction it can provide to an investigation where all other leads have
gone cold, it's a reasonable price. The price is not much different from
the expense incurred interviewing human eyewitnesses, yet the
information provided is better than what most eyewitnesses can provide,
said Tony Frudakis, PhD and CSO of the company. "Though our test can
accurately distinguish between an individual of mainly Native
American/European admixture (such as a Hispanic) from one of mainly
European/East Asian admixture (such as an Asian American), a human from
across the street might be hard pressed to do so reliably. This test is
the only one of its kind. We have worked hard over the last four years
building the test and validating it." He continued, "The test is a
presumptive test that can be used by investigators to get a basic
description out on the wire to other investigators and departments. It
is an investigator's tool, not an identity tool. Once the pool of
suspects has been narrowed down, then the standard DNA identity testing
can be performed, under court order if necessary, to substantiate the
potential guilt or innocence of an individual suspect."
"I know if it were my daughter or son that had been murdered or raped,
I would want this test run." said Zach Gaskin, Technical Director of
Forensics. "I frequently give lectures on how our test works and how to
use it. DNA WitnessT is becoming known as a reliable test for law
enforcement across the country and abroad, allowing them to narrow their
field of suspects rapidly. Because DNA WitnessT is a presumptive DNA
test providing information as to how the donor of the DNA sample is
likely to appear or not appear, essentially producing an out-of-focus
photo, it will not likely meet the same scrutiny in the courtroom as the
human identification tests that match a suspect to a crime scene sample.
Nevertheless, we treat the evidence in accordance with policies and
procedures followed by the American Society of Crime Laboratory
Directors Lab Accreditation Board. It is important to note that the
current human identification DNA tests performed by crime labs, known as
STR tests, can only provide gender when you have no suspect to compare
the evidence to. STR testing for criminal cases does require ASCLD/LAB
certification because it actually identifies the individual as the
person present at the crime scene." Gaskin went on to say "DNA WitnessT
provides a general description of the person, not a match, which we
leave to the crime labs. But DNA WitnessT is an extremely valuable tool
for helping detectives narrow the suspect list and focus their resources
on leads that are more in line with the crime scene evidence."
About DNAPrint(TM) genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods
to develop and sell genomic-based services. The Company introduced
AncestrybyDNA in the consumer market and DNA Witness in the forensic
market in 2003. DNAPrint is developing products in the pharmacogenomic
market and has a disease gene discovery program. The Company is traded
on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more
information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act as amended. Such statements are subject to risks
and uncertainties that could cause actual results to differ materially
from those projected, including, but not limited to, uncertainties
relating to technologies, product development, manufacturing, market
acceptance, cost and pricing of DNAPrint's products, dependence on
collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation.
DNAPrint genomics, Inc. expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint Genomics, Inc.
CEO/President
(941) 366-3400
Another arm to the Comp. - http://www.jmpharma.com/
Here's Johnson Matthey - http://www.jmusa.com/index.html
They have a Virtual Tour just click the window its really great take a look.
Here's their web take a look - http://www.pharmeco.com/
Pharm-Eco unveils new small manufacturing facility and cryogenic cooling capabilities.
Devens, MA – Pharm-Eco, A Johnson Matthey Company unveiled its two new reactor suites today, signaling the completion of the first phase in their Devens, MA pilot plant expansion as well as the launch of a new capability, cryogenic cooling.
Each 3 floor suite is equipped with three reactors plus its associated auxiliary equipment. Suite A has a 100 gallon glass lined reactor, plus a 200 gallon hastelloy reactor with cryogenic cooling capabilities. Suite B has a 200 and 500 gallon glass lined reactor as well as a 500 gallon hastelloy reactor, also with cryogenic cooling capabilities.
The addition of the suites and cryogenic capabilities to their two existing pilot plants and 32 kilo labs brings a new dynamic to Pharm-Eco’s ability to completely serve a client’s needs by taking a drug from early stage discovery/medicinal chemistry all the way to commercialization. Dr. S.A. Zahr, General Manager and Executive Vice President of Pharm-Eco, thinks the additions are a win-win situation for both Pharm-Eco and their clients.
“Our goal is to enable our clients to succeed in their discovery, development and production of API by getting them to market faster through innovative, cost efficient chemistry services. The addition of the suites is a win-win situation for both us and the clients whose needs we serve. Continued growth as well as integrating our experience, capabilities, facilities, and resources with fellow Johnson Matthey Pharmaceutical Materials Division members and other Johnson Matthey business units, enables us to provide our clients with the complete development solution,” said Zahr.
The building in which the new suites are housed is designed to allow for at least six additional similar reactor suites in the future.
Pharm-Eco expands service offerings
Devens, MA – Pharm-Eco, a Johnson Matthey Company and part of Johnson Matthey’s Pharmaceutical Materials Division, announced today that their Analytical/Quality Control and Regulatory Compliance services, which were previously offered in conjunction with existing project contracts, will now be offered independently as well.
Pharm-Eco is an outsourcing company that enables their clients to succeed in their discovery, development and production of API by getting them to market faster through innovative, cost efficient chemistry services. Their service areas encompass the entire drug development cycle, from early stage discovery through commercial manufacturing.
Addressing the growing needs of the industry, the new independent service offerings will be modeled after Pharm-Eco’s exemplary, rigorous in-house Quality system that is currently used for all existing projects. Analytical/QC services include analytical methods, analytical method validation, analytical method transfer, compendial testing, impurity profiles, impurity identification, reference standard development and characterization, structure elucidation, and stability services.
Amongst the Regulatory Services are support for Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Abbreviated New Drug Applications (ANDAs); Authoring the Chemistry and Manufacturing Controls (CMC) section of regulatory filings, providing sections of the filing, or performing a compliance review; Authoring Type II Drug Master Files (DMFs) and providing letters of reference; Obtaining cGMP certificates for drug substance as well as filing compendial monographs in the US and Europe.
Pharm-Eco will also provide auditing services utilizing a combined 60+ years of expertise in that area. Rounding out the service offering will be training services based on Pharm-Eco’s highly developed training modules in all critical areas of operations.
For more information on this or other services provided by Pharm-Eco, please contact Harwood “Woody” Stiles, Director, Quality at 978-784-5000.
Theo, remember Tony also said our move to Nasdac would NOT be done by a lot of small moves BUT by a few very big moves.
ann441j,i have already gone through city's that start with a,b,c, and d's I hit their police Dept.Frome their chief down to the Captains and Detective units as well as the Mayor and DA office in each town.This does not take as long as you may think.
Theo,how do you get a guy {who has no needs} who's living and working in Mass. to drop everything or step away from his Busy day to come all the way down to Fl. to some small Comp. like Dnap.This guy really had no need he's co-owner of Pharm-Eco,a very big and profitable and demanding Bus.And served as Chief Executive Officer and President of Calix Corporation you know it didn't just end there at Calix. This guy is making moves. What brought him to Dnap. Who brought him to Dnap.He's still going back and forth - Why. And why did Tony give such a great deal to him to come on board ? I should think it s very clear as to why.Look at all the "whys" and "Hows" you come up with after reading the Wall Street Interview.A 100 more employees within a year- How !!By the end of 2 years a Pharmaceutical company - How !! Moving to a much bigger place - How !! "our Business is about helping Dnaprint develop the most powerful drugs that have ever been developed" - HOW !!! All these questions can be answered very easy by a buy out or merger with Pharm-Eco. they have the space for Dnap to move in and set up shop there,they have just about every thing else Dnap would need as well. Jersy is just around the conner so getting more Snip machines is no problem once they merg, Tony will have the money to buy 10 Snip machines and more.Ask your self how big of a Buld. do you need for a 100 Employees, come on Dnap is going to move all right to Mass.Johnson Matthey Company is no small Comp.and they can make things happen with Dnap. Richard Gabriel is a Captain of industry he's bigger than most think he's a very powerful man and knows a lot of powerful people he not one to waste time going no where.This is going to happen just as Tony has said and its going to be Big Big Big BIg.
Tony has to go some where to set this all up why in the hell would he go anywhere else but down the Hall it makes no sense.
This is going to happen I'll bet the Farm on it.
Richard is CO-OWNER of this comp. one way or another he's involved. Remember Tony said Dnap needs a Bigger place in 2 years we will have our own drugs and what was it 150 employees within a year ?? Come on this is getting better and better Its perfect.
Pharm-Eco expands service offerings
Devens, MA – Pharm-Eco, a Johnson Matthey Company and part of Johnson Matthey’s Pharmaceutical Materials Division, announced today that their Analytical/Quality Control and Regulatory Compliance services, which were previously offered in conjunction with existing project contracts, will now be offered independently as well.
Pharm-Eco is an outsourcing company that enables their clients to succeed in their discovery, development and production of API by getting them to market faster through innovative, cost efficient chemistry services. Their service areas encompass the entire drug development cycle, from early stage discovery through commercial manufacturing.
Addressing the growing needs of the industry, the new independent service offerings will be modeled after Pharm-Eco’s exemplary, rigorous in-house Quality system that is currently used for all existing projects. Analytical/QC services include analytical methods, analytical method validation, analytical method transfer, compendial testing, impurity profiles, impurity identification, reference standard development and characterization, structure elucidation, and stability services.
Amongst the Regulatory Services are support for Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Abbreviated New Drug Applications (ANDAs); Authoring the Chemistry and Manufacturing Controls (CMC) section of regulatory filings, providing sections of the filing, or performing a compliance review; Authoring Type II Drug Master Files (DMFs) and providing letters of reference; Obtaining cGMP certificates for drug substance as well as filing compendial monographs in the US and Europe.
Pharm-Eco will also provide auditing services utilizing a combined 60+ years of expertise in that area. Rounding out the service offering will be training services based on Pharm-Eco’s highly developed training modules in all critical areas of operations.
For more information on this or other services provided by Pharm-Eco, please contact Harwood “Woody” Stiles, Director, Quality at 978-784-5000.
Pharm-Eco unveils new small manufacturing facility and cryogenic cooling capabilities.
Devens, MA – Pharm-Eco, A Johnson Matthey Company unveiled its two new reactor suites today, signaling the completion of the first phase in their Devens, MA pilot plant expansion as well as the launch of a new capability, cryogenic cooling.
Each 3 floor suite is equipped with three reactors plus its associated auxiliary equipment. Suite A has a 100 gallon glass lined reactor, plus a 200 gallon hastelloy reactor with cryogenic cooling capabilities. Suite B has a 200 and 500 gallon glass lined reactor as well as a 500 gallon hastelloy reactor, also with cryogenic cooling capabilities.
The addition of the suites and cryogenic capabilities to their two existing pilot plants and 32 kilo labs brings a new dynamic to Pharm-Eco’s ability to completely serve a client’s needs by taking a drug from early stage discovery/medicinal chemistry all the way to commercialization. Dr. S.A. Zahr, General Manager and Executive Vice President of Pharm-Eco, thinks the additions are a win-win situation for both Pharm-Eco and their clients.
“Our goal is to enable our clients to succeed in their discovery, development and production of API by getting them to market faster through innovative, cost efficient chemistry services. The addition of the suites is a win-win situation for both us and the clients whose needs we serve. Continued growth as well as integrating our experience, capabilities, facilities, and resources with fellow Johnson Matthey Pharmaceutical Materials Division members and other Johnson Matthey business units, enables us to provide our clients with the complete development solution,” said Zahr.
The building in which the new suites are housed is designed to allow for at least six additional similar reactor suites in the future.
I'm telling ya this is it, read about this comp. and put the peices togeather.
This is why Gabriel is going back and forth to Mass. I see a merger here and soon. Tony was talking about being a pharmaceutical comp. in 2 years our CEO owns one thats up and running it has cgmp, customers made 17 million last year. This is it man i'm putting my BET Down my chips are on Gabriel and this is BIg.Johnson Matthey is $17.00 per share. Now I could be wrong but i'm betting i'm not.Dnap a Drug Comp. in a year or 2. Gabriel's Comp.'s main thrust is dealing with phase 1 and phase 2 trials for Drug approval and phase 3.
And this is very Big - API, Cedarburg and Pharm-Eco Offer Stateside cGMP Alternatives.
Chemical Market Reporter, Dec 7, 1998, by Clay Boswell
EUROPE HAS TRADITIONALLY held the lion's share of cGMP custom manufacturing, but three ambitious young companies- Pharm-Eco, Lexington, Mass.; API Inc., Fairfield, N.J.; and Cedarburg Laboratories, Grafton, Wis.-are greatly enhancing stateside production.
Cedarburg is targeting pharmaceutical intermediates and actives for use in studies that range from preclinical through phase III clinical trials, in quantities from 200 grams to 200 kilos. The company's kilo lab began operations in March and production in June. "We're doing quite well," says Charles Boland, executive vice-president at Cedarburg. The former Hoffmann-LaRoche executive says the company's rapid success demonstrates a growing market for cGMP capabilities. "All of our capacity is sold out for the rest of the year," he notes.
The Grafton site is completely new. "We went to a number of prospects," Mr. Boland says, "and asked, 'If you could design a facility that would meet your needs in the smaller range of production volume, what would you like to see?'"
Drawing on the answers they received, Cedarburg built a totally cGMP facility with four isolated manufacturing suites. Each features a separate HVAC system with a minimum of 100,000-class air and a 50-, 100-, 300- or 500-gallon reactor train. In addition, three separate chemistry labs allow customers to address scale up and other chemical questions on-site without encountering competitors.
"We aren't focusing on particular technologies," says Mr. Boland. "What we are interested in is complex organic synthesis-high value projects such as pharmaceutical intermediates and actives. We offer responsiveness and the ability to handle a wide range of chemistries."
Bob Koch, president of API Inc., discovered the US cGMP scarcity first-hand when he oversaw the outsourcing that preceded closure of Hoffmann-LaRoche's Nutley chemical manufacturing plant. At that time, Mr. Koch also discovered the market niche that led to the formation of API. "I was having trouble finding vendors for some of our low-volume products, when I realized that some of these things can be made on a lab scale," he says.
API's specialty is the small scale, cGMP manufacture of active pharmaceutical ingredients. "There are many drugs around that are truly needed by a devoted customer base, but in small volumes, so most companies are not interested in making them," Mr. Koch says. "We think we know how to do that economically with validated, cGMP synthesis."
API has labs for analysis, development and manufacturing, as well as a clean room with capability to class 10,000. Quantities of finished pharmaceutical actives range from 1 to 100 kilos.
Most of API's targets have thus far been products transferred from major pharmaceutical companies to their smaller brethren-products that are typically off-patent but not truly orphan drugs. In such cases, the originator of the drug will have provided the new marketer with enough of the drug or pharmaceutical active to last up to three years. "Then they're on their own to find new sources-usually a difficult task," says Mr. Koch. "That's where we come in."Mr. Koch says that API can also perform other, more specialized work. "Because of our association with Roche, we have unique experience with vitamins and their derivatives.
Founded in 1971, Pharm-Eco is a much older business than Cedarburg Labs or API, but it was essentially reborn in 1992. That year, when Pharm-Eco was purchased by three investors, it was a $1.5 million California corporation of 20 employees, largely supplying clinical materials to the National Institutes of Health.
The business was shortly moved to Massachusetts, where it has since expanded to 140 employees, including 88 chemists, 30 of which hold PhDs, and seven chemical engineers. The group also features a four-member team for molecular modeling, rational drug design and statistical reaction design, and a full-time computer programmer.
"We saw the direction of outsourcing," says co-owner Richard Gabriel, "so we positioned our company to supply value-added technologies. Though the idea of sharing intellectual property was inconceivable to the large pharmaceutical companies six years ago, we have since shown many customers and clients that trusting and sharing will not only speed the drug development process but also reduce risk."
Drugs fail for many reasons, Mr. Gabriel points out. Enlisting the services of a dedicated firm such as Pharm-Eco means a better understanding of the chemistries involved, higher purities and safer drugs more likely to reach the market. "You have to go back to good science, and that's what we do," he says. "We create technologies that enable, not disable. So we are always looking for partnering, joint ventures and sharing relationships."
Mr. Gabriel cites United Pharma Technologies (UPT) as an example. A 5 0-50 JV with Des Plaines, Ill.-based UOP, UPT was established to adapt UOP's simulated-moving-bed (SMB) chromatographic technology.
"We've taken a technology proven in the oil refining industry, refined it and made it commercially viable for the pharmaceutical industry under cGMP conditions," says Mr. Gabriel. Capable of chiral separations, SMB can speed the drug development process by obviating asymmetric synthesis. "We just completed a 20-kilo run, and we're going into a 300-kilo run," he adds. "The unit itself will do 15 to 20 tons under cGMP conditions-the first that we're aware of in the US."
Pharmaceutical outsourcing can only grow, says Mr. Gabriel, and Pharm-Eco is preparing itself with a three-phase expansion program. Ground will be broken this month in Devens, Mass., for the first phase, a new 135,000-square-foot facility to be completed in late 1999 at an estimated cost of $35 million. It will include 52 cGMP laboratories, a pilot plant with 500gallon reactors, a dedicated robotics laboratory for combinatorial chemistry, UPT's SMB technology, and comprehensive analytical services.
The second phase will expand the facility to 580,000 square feet with increased reactor capacities up to 4,000 gallons to allow the manufacture of bulk pharmaceutical actives. "We have a number of relationships with pharmaceutical companies that will hopefully emerge as approved drugs in the next five years. Should they, we want to supply at least a portion of the active ingredient," explains Mr. Gabriel. By then, he expects the company's staff to have grown to 1,500.In the third phase, Pharm-Eco will become a full-service manufacturer offering the formulation and packaging of drug product for distribution and sale. "Other companies can provide material," Mr. Gabriel says. "We want to be a full outsourcing partner
Better Read this as well -
Johnson Matthey Acquires Pharm-Eco Laboratories
Johnson Matthey announces that it has acquired Pharm-Eco Laboratories, Inc. ("Pharm-Eco") for a cash consideration of US$9.9 million. In addition, Johnson Matthey has taken on Pharm-Eco's net borrowings of US$37.0 million.
Based on two sites in the Boston, Massachusetts area and employing around 120 people, Pharm-Eco provides contract research, process development and small scale synthesis services to the pharmaceutical industry. Its turnover in the financial year ended 31st December 2000 was $17 million.
Pharm-Eco's services are primarily focussed on drug development from discovery through to Phase II clinical trials. These services complement Johnson Matthey's Pharmaceutical Materials business, based at West Deptford, New Jersey, which manufactures active pharmaceutical ingredients for drugs that are already approved for market or are very near to receiving final approval.
The acquisition presents Johnson Matthey with enhanced opportunities to bring new pharmaceutical manufacturing business to the West Deptford facility, which is currently undergoing a major programme of expansion, and considerably extends its existing portfolio of products and services for customers in the pharmaceutical industry.
The acquisition of Pharm-Eco is expected to be earnings neutral in Johnson Matthey's current financial year and earnings enhancing thereafter.
Commenting on the acquisition, Chris Clark, Chief Executive of Johnson Matthey said:
"Niche acquisitions in our core business areas are in line with our strategy for growth. We are also investing heavily in our existing businesses. The acquisition of Pharm-Eco represents an excellent opportunity to further expand our activities in the rapidly growing pharmaceutical materials market."
Forrest Sheffy, Vice President and General Manager, Pharmaceutical Materials, said:
"Pharm-Eco has a strong customer base and an outstanding reputation for the quality of its service throughout the pharmaceutical industry. The acquisition fits well with our existing activities in pharmaceutical materials."
Enquiries:
Johnson Matthey
John Sheldrick
Group Finance Director
020 7269 8438
Forrest Sheffy
Vice President and General Manager,
Pharmaceutical Materials
(+1) 856 384 72
Ian Godwin
Group Corporate Communications Manager
020 7269 8410
Better look at this again I got a very very strong feeling its what Tony was talking about a year or 2 from now. - Richard Gabriel, BS, MBA, CEO/ President
From 1998 until 2001 Mr. Gabriel served as Chief Executive Officer and President of Calix Corporation, parent company to Pharm-Eco Laboratories, Inc. He was one of five core team members that set the overall strategic direction for Pharm-Eco Laboratories, Inc. and helped guide Pharm-Eco's high performance self-directed organization[/b}. Mr. Gabriel was instrumental in closing and managing over $135 million in contract revenue for Pharm-Eco Laboratories and successfully completed the formation of several joint ventures, limited liability companies and spin-offs that resulted in several public and private companies in the genetics/chemistry/pharmaceutical field. From 2001 until becoming the Chief Executive Officer and President for DNAPrint, he consulted for several start-up companies while working as a partner at Genbiomics, LLC and as head of Life Sciences Practice at Semaphore, Inc. Prior to the formation of his own consulting practice in 1985, Mr. Gabriel was a product manager for W.R. Grace. He obtained his MBA from Suffolk University's Executive MBA Program, Boston, Massachusetts, in 1985, and his B.S. in Chemistry from Ohio Dominican College, Columbus, Ohio in 1978.
I'll be done with the whole State before the end of the week !!!!!
Look heres what I'm working on Now,including the DA's office and mayor's office in each city - http://www.usacops.com/co/pollist.html
Here's another site to help you make a list of contacts - http://www.neafs.org/labs.htm
Here is some more places to send info. to - http://www.neafs.org/labs.htm
Call or write your local DA's office and police Dept. about Dnap
Eye Color out soon !!! And then we go to the Mooooooooooonnnnnn
Ming Shriver has more under his wings than Bayer has aspirin.
Ok thanks Ming. very good pics I know the sun is going down where you are so have a good night.Thanks again for the - {Let's see, apart from anybody else, you missed: Joshua Akey, Ranjan Deka, Bob Ferrell, Peter Underhill, William Garvey, Eric Boerwinkle, Ranajit himself, Richard Cooper, Mike Seldin, Michael Smith, David Stivers, Connie Mulligan, Kenneth Weiss, Kateryna Makova, Andrew Clark, Indrani Halder, Jen Wagner, and George Argyropoulos to name a few}.
Ming are you Talking about Hector Gomez's side of people or Mark Shriver side of people or maybe D.C. Rao PhD
Ok Ming you asked for it Know -"I triple dog Dare" you to give us the Names.
Ming dont make me say it in my next post if you dont give us the names I will be forced to use a Dare. Give us the names or my next post will have "the Dare" in it.
Ming dont you go to bed yet give us those names.
Ok Ming spell them out.LOL Lets have their names Dont tease.LOL
Ming. if Dnap would come out with Eye Color we could get Ranajit Chakraborty on Board with us.That would be BIG.
Ok so helping Tony with Java is Ponnuswamy,V and Gunjipulli,S.some new Kid from New College and a Russian programmer.Thats 4 on Programming and software.
But Make no mistake Mark Shriver does not work alone or with just a few helping out. He Has by his side one way or another The following - Allison,A;Esteban Parra J.;Alice S. Ryan:N. Patel;C.PFaFF; Paul McKeigue; Barbara Nicklas;Wake Forest;Jeanine Albu;Roland L.Weinsier;Clive L.Hoggart;Mark T. beasley;Sania Dios;Aisha Massac;Neil Cameron;Rick Kittles;LI Jin;Cecily Jones;Carolina Bonilla;Heather Norton;Archie Baron;Celina Jovel and there's more.
Jose Fernandez & David B. Allison are at the top of the list for important people who work with Mark Shriver.
In Journal of Forensic Sciences - a List of some of the employees -
Stock #: JFS0307
Volume: 48
Issue: 4
Year: 2003
Pages: 771-782
Author(s): Frudakis T, Kondragunta V, Thomas M, Gaskin Z, Ginjupalli S, Gunturi S, Ponnuswamy V, Natarajan S, Nachimuthu PK
Title: A classifier for the SNP-based inference of ancestry
Keywords: AHR, ancestry, AP3B1, battery, classification, CYP1A1, CYP2C8, CYP2C9, CYP2D6, CYP3A4, DCT, DNA typing, ethnicity, forensic science, genotype, MCIR, OCA2, single nucleotide polymorphism, TYRP1
Abstract: Ancestral inference from DNA could serve as an important adjunct for both standard and future human identity testing procedures. However, current STR methods for the inference of ancestral affiliation have inherent statistical and technical limitations. In an effort to identify bi-allelic markers that can be used to infer ancestral affiliation from DNA, we screened 211 SNPs in the human pigmentation and xenobiotic metabolism genes. Allele frequencies of 56 SNPs (most from pigmentation genes) were dramatically different between groups of unrelated individuals of Asian, African, and European descent, and both observed and simulated log likelihood ratios revealed that the markers were of exceptional value for ancestral inference. Log likelihood ratios of the multilocus estimates of biological ancestry (EAE/EBA) ranged from 7 to 10, which are on par with the best of the STR batteries yet described. A linear classification method was developed for incorporating these SNPs into a classifier model that was 99, 98, and 100% accurate for identifying individuals of European, African, and Asian descent, respectively. The methods and markers we describe are therefore an important first step for the development of a practical multiplex test for the inference of ancestry in a forensics setting.
This should keep you - hint - Paul M. Mckeigue - http://www3.interscience.wiley.com/cgi-bin/jhome/35841